Xlife Sciences Ltd.
8.62
CHF
-3.96
(-31.47%)
ISIN
CH0461929603
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Oliver R. Baumann
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Zurich Switzerland
- IPO Date
- Sep 30, 2019
- Website
- xlifesciences.ch
- Similar Companies
- Business
- Xlife Sciences Ltd. is a Zurich, Switzerland-based life sciences incubator, accelerator, and investment management company focused on the development and commercialization of early-stage biomedical research, healthcare technologies, and academic intellectual property. Founded in 2019, the company bridges the gap between university research institutions and healthcare markets by identifying preclinical scientific discoveries, establishing dedicated project companies, and advancing assets through proof-of-concept validation, patent protection, regulatory strategy, and commercial exits. The company operates across four core business segments: Therapeutics, comprising biopharmaceuticals, novel antibody-drug conjugates, immunotherapies, oncology treatments, neurological formulations, and metabolic disease therapies; Diagnostics, encompassing non-invasive screening platforms, biomarker identification systems, point-of-care testing tools, and early-stage disease detection solutions; Technology Platforms, featuring artificial intelligence-driven diagnostic software, microfluidic systems, advanced drug formulation technologies, and three-dimensional pharmaceutical manufacturing platforms; and Medical Technology, consisting of bio-compatible implants, surgical devices, regenerative wound-care systems, and digital health applications. In addition to technical development, Xlife Sciences provides comprehensive project management, intellectual property structuring, preclinical trial management, regulatory compliance oversight, and transaction structuring encompassing out-licensing, trade sales, joint ventures, and public listings. Geographically, the company operates primarily across Switzerland, Germany, and the broader European region, with expanding strategic development initiatives in the Middle East and North America. Recent major operational and strategic developments include expanding international operations into the United Arab Emirates through strategic collaboration agreements with the Department of Health – Abu Dhabi to establish regional life sciences innovation hubs and clinical development programs; advancing commercial milestones across its artificial intelligence diagnostic portfolio, including regulatory clearances and international software distribution agreements; and progressing portfolio monetization through out-licensing arrangements, project company capital increases, and targeted portfolio reallocations designed to accelerate commercial-stage exits.